Aayush Wellness Ltd (539528)
📢 Recent Corporate Announcements
Aayush Wellness Limited announced the launch of its 'Lung Care Tablets', entering India's ₹18,913 crore respiratory healthcare market. The company cited industry figures noting that the domestic respiratory therapeutic segment grew ~10% YoY from ₹17,199.40 crore in 2024 to ₹18,912.64 crore in 2025. The product formulation combines N-Acetyl Cysteine (NAC), Vasaka Extract, Licorice, Quercetin, Vitamin C, Vitamin D2, and Zinc to target pollution and smoking-related respiratory concerns. No specific revenue targets, capital expenditures, or launch costs were disclosed in the filing.
- Targets India's ₹18,912.64 crore respiratory healthcare therapeutic market (2025 sales, up from ₹17,199.40 crore in 2024).
- Addresses market where India accounts for 15.69% of global chronic respiratory disease cases and 30.28% of global deaths.
- Formulation includes 7 key active components: NAC, Vasaka Extract, Licorice, Quercetin, Vitamin C, Vitamin D2, and Zinc.
- Complements existing preventive portfolio, expanding beyond the tobacco-alternative herbal masala vertical.
Aayush Wellness reported a strong Q1 FY27 with consolidated revenue rising 46.3% YoY to ₹33.11 crore. Profit After Tax (PAT) grew 22.6% YoY to ₹1.42 crore, showing a significant sequential recovery of 150.8% compared to Q4 FY26. Earnings Per Share (EPS) improved to ₹0.29 from ₹0.24 in the year-ago period. The growth was driven by digital commerce scaling and improved distribution efficiency across its preventive healthcare portfolio.
- Consolidated Revenue from Operations reached ₹33.11 crore, a 46.3% increase over Q1 FY26.
- Profit After Tax (PAT) surged 150.8% quarter-on-quarter to ₹1.42 crore.
- Earnings Per Share (EPS) increased to ₹0.29 from ₹0.24 YoY and ₹0.12 QoQ.
- Company is evaluating export opportunities in the Middle East (UAE) and South Asia to diversify revenue.
- Operating leverage and cost discipline cited as primary drivers for the sharp sequential profit increase.
Aayush Wellness reported a strong start to FY27 with consolidated revenue growing 46.3% YoY to ₹33.11 Cr. Profit After Tax (PAT) saw a significant sequential recovery, jumping 150.8% QoQ to ₹1.42 Cr from ₹0.56 Cr in the previous quarter. While YoY PAT growth was more modest at 22.6%, the company is showing signs of improved operating leverage. However, the business continues to operate with thin margins and a unique 0% promoter holding structure.
- Consolidated revenue from operations increased to ₹33.11 Cr, up 46.3% from ₹22.63 Cr in Q1 FY26.
- Consolidated PAT reached ₹1.42 Cr, representing a 150.8% growth over the preceding quarter (Q4 FY26).
- Earnings Per Share (EPS) improved to ₹0.29 for the quarter, compared to ₹0.24 in the year-ago period.
- Standalone revenue stood at ₹24.07 Cr, contributing approximately 73% of the total consolidated top-line.
- Total expenses for the standalone entity were ₹23.52 Cr, with stock-in-trade purchases accounting for nearly 98% of costs.
Aayush Wellness reported a 46.3% YoY increase in consolidated revenue to Rs 33.11 Cr for Q1 FY27. Consolidated Profit After Tax (PAT) grew 22.6% YoY to Rs 1.42 Cr, while showing a significant 150.8% sequential (QoQ) recovery from Rs 0.56 Cr in Q4 FY26. The company attributes this growth to product portfolio expansion and digital commerce scale-up. However, standalone revenue saw a sharp sequential decline, dropping from Rs 48.40 Cr in the previous quarter to Rs 24.07 Cr.
- Consolidated revenue reached Rs 33.11 Cr, a 46.3% increase over the Rs 22.63 Cr reported in Q1 FY26.
- Consolidated PAT stood at Rs 1.42 Cr, representing a 150.8% QoQ jump from Rs 0.56 Cr in the preceding quarter.
- Standalone revenue of Rs 24.07 Cr accounts for approximately 73% of consolidated revenue, indicating growing subsidiary contributions.
- Earnings Per Share (EPS) improved to Rs 0.29 from Rs 0.24 in the same quarter last year.
- Standalone total expenses were managed at Rs 23.52 Cr against a total income of Rs 24.72 Cr.
Aayush Wellness has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This follows a year of significant revenue scaling to Rs 155 Cr in FY26, though operating margins remain thin at 1.0%. Investors will be monitoring the results for traction in the new Herbal Pan Masala segment and the $3M Singapore export pipeline. The trading window, closed since July 01, 2026, will reopen 48 hours after the results are announced.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results
- Trading window has been closed since July 01, 2026, per insider trading regulations
- Company reported a TTM revenue of Rs 155 Cr with a low OPM of 1.2%
- Promoter holding remains at 0.0% as per the latest available financial context
Aayush Wellness Limited has approved the appointment of M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy. The board also approved the regularization of two Non-Executive Non-Independent Directors, Mr. Dinesh Dhangare and Mr. Kashiram Jadhav. A postal ballot will be conducted to seek shareholder approval for these changes, with the e-voting period running from July 19, 2026, to August 17, 2026. The cut-off date for voting eligibility is July 10, 2026.
- Appointment of M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy
- Regularization of 2 Non-Executive Non-Independent Directors approved by the board
- Postal ballot e-voting period scheduled for 30 days starting July 19, 2026
- Cut-off date for shareholder voting eligibility set as July 10, 2026
Financial Performance
Revenue Growth by Segment
Total revenue grew by an extraordinary 8,645% YoY, reaching INR 73.39 Cr (7,338.59 lakhs) in FY25 compared to INR 0.84 Cr (83.92 lakhs) in FY24. While specific segment-wise percentage splits are not provided, growth was driven by the launch of nutraceuticals, herbal pan masala, and the expansion into export markets.
Geographic Revenue Split
The company is diversifying from a purely domestic focus to international markets, notably securing a US $3 million (approx. INR 25.2 Cr) export order from Singapore, which represents roughly 34% of the current annual revenue run rate. Domestic revenue is driven by pan-India distribution and e-commerce platforms like Amazon.
Profitability Margins
Net Profit Margin stood at 5% in FY25, a significant decrease from 98% in FY24. This compression is due to the transition from a low-volume, low-cost operation to a high-scale commercial model with increased marketing, distribution, and raw material costs. Net profit increased 489% in absolute terms to INR 3.37 Cr.
EBITDA Margin
EBITDA Margin was 4.6% in FY25, down from 70.8% in FY24. The sharp decline reflects the high operational costs associated with scaling revenue by over 8,000% and the introduction of mass-market products like INR 10 sachets which carry lower margins than niche offerings.
Capital Expenditure
The company has planned a capital expenditure of INR 30 Cr over the next two years to establish world-class wellness centers. Additionally, it allocated INR 5 Cr (50 million) to a Strategic Growth Division for investments in healthcare startups.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company strengthened its equity base by increasing authorized share capital from INR 3.5 Cr to INR 9 Cr during the period.
Operational Drivers
Raw Materials
Specific raw materials include herbal extracts for pan masala and nutraceutical ingredients for gummies (vitamins, minerals). While exact percentage of total cost is not disclosed, the shift to a 5% net margin suggests raw materials and procurement are now the primary cost drivers.
Import Sources
Not specifically disclosed, but the company operates out of New Delhi and Maharashtra, suggesting primary sourcing from Indian botanical and chemical hubs.
Capacity Expansion
The company is expanding from a product-only model to a service model by launching its own healthcare centers and wellness tourism centers (INR 30 Cr investment) to create a scalable platform for preventive care.
Raw Material Costs
Raw material costs have surged as a percentage of revenue, contributing to the drop in EBITDA margin from 70.8% to 4.6%. The company is utilizing a high-volume, mass-market strategy (INR 10 sachets) to drive penetration.
Manufacturing Efficiency
The company demonstrated the ability to scale revenue by 8,645% within a single fiscal year, indicating a highly scalable outsourced or asset-light manufacturing and distribution model.
Logistics & Distribution
The company utilizes an omni-channel strategy including Amazon for digital reach and a leading distributor in Singapore for international logistics, aiming to reduce internal logistics overhead.
Strategic Growth
Expected Growth Rate
5%
Growth Strategy
Growth will be achieved through a multi-vertical approach: 1) Export expansion via a US $3M Singapore order; 2) Product diversification into the INR 46,000 Cr pan masala market with a tobacco-free herbal alternative; 3) Launching wellness centers with an INR 30 Cr investment; and 4) Digital scaling on Amazon for nutraceuticals.
Products & Services
Herbal Pan Masala, Dreamy Sleep Gummies, Beauty Vitamin Gummies, Telemedicine services, Online Diagnostics, and Wellness Tourism packages.
Brand Portfolio
Aayush Wellness, Aayush Healthsciences, Aayush Worldwide.
New Products/Services
Recently launched Herbal Pan Masala and Healthcare centers; wellness tourism is expected to contribute to revenue over the next 24 months following the INR 30 Cr investment.
Market Expansion
Formal entry into the Singapore market (valued at USD 1.03 billion by 2033) and shifting the registered office to Maharashtra to tap into the western Indian commercial hub.
Strategic Alliances
Partnership with M/s Cosmos Holdings Pte Ltd for Singapore distribution and planned collaborations with government tourism boards for wellness centers.
External Factors
Industry Trends
The Indian health and wellness sector is growing at 5% annually. There is a structural shift from reactive treatment to preventive care, which the company is capturing through its new healthcare centers and nutraceutical range.
Competitive Landscape
Competes with established large-scale healthcare infrastructure players and emerging digital-first wellness startups.
Competitive Moat
The moat is built on a 'multi-vertical presence' blending traditional Ayurveda with modern delivery formats (gummies, sachets). This is sustainable due to the high cost for competitors to replicate an omni-channel presence spanning exports, retail, and physical wellness centers.
Macro Economic Sensitivity
Highly sensitive to Indian GDP growth (6.5% in FY25) and Private Final Consumption Expenditure (PFCE), as wellness products are discretionary consumer goods.
Consumer Behavior
Rising lifestyle-related health issues and a shift toward preventive, affordable healthcare (INR 10 sachets) are driving demand for the company's herbal alternatives.
Geopolitical Risks
Trade uncertainties and geopolitical tensions are noted as headwinds, though the company's entry into Singapore serves as a gateway to Southeast Asia to diversify geographic risk.
Regulatory & Governance
Industry Regulations
Operations are governed by the Companies Act 2013 and SEBI (LODR) Regulations. The company must comply with food and drug standards for its nutraceutical and herbal products in both India and Singapore.
Legal Contingencies
No pending court cases or case values were disclosed in the secretarial or auditor reports provided.
Risk Analysis
Key Uncertainties
The primary uncertainty is the sustainability of the 8,645% revenue growth rate and whether the 5% net profit margin can be maintained or improved as marketing costs for new products rise.
Geographic Concentration Risk
While expanding, the company remains heavily dependent on the Indian market and a single major export contract in Singapore.
Third Party Dependencies
High dependency on M/s Cosmos Holdings for Singapore market access and Amazon for digital sales fulfillment.
Technology Obsolescence Risk
The company is mitigating tech risks by integrating AI-based diagnostics and telehealth into its new healthcare centers.
Credit & Counterparty Risk
The US $3 million export order introduces counterparty credit risk with Cosmos Holdings Pte Ltd.
